Clinical Trial

A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH

Study acronym: ZENITH-2
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study will evaluate the safety and tolerability of Efimosfermin Alfa for participants with known or suspected MASH with fibrosis consistent with stage F2 or F3.
Protocol Amendment History 1 change
notable Trial sites expanded: 6 -> 43 locations 2026-04-17
Trial Details
NCT Number NCT07221188
Lead Sponsor GlaxoSmithKline
Conditions Non-alcoholic Fatty Liver Disease
Enrollment 1,250 participants
Start Date 2025-12-12
Primary Completion 2028-03-24 (estimated)
Study Completion 2028-03-24 (estimated)
Updated on ClinicalTrials.gov 2026-04-16